(VIANEWS) - Shares of Seattle Genetics (NASDAQ: SGEN) rose by a staggering 15.72% to $199.74 at 10:18 EST on Monday, after four successive sessions in a row of losses. NASDAQ is sliding 1.76% to $11,138.89, after two consecutive sessions in a row of losses. This seems, so far, an all-around down trend exchanging session today.
Seattle Genetics's last close was $172.61, 5.68% under its 52-week high of $183.00.
About Seattle Genetics
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Earnings Per Share
As for profitability, Seattle Genetics has a trailing twelve months EPS of $3.58.
PE Ratio
Seattle Genetics has a trailing twelve months price to earnings ratio of 55.73. Meaning, the purchaser of the share is investing $55.73 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -21.27%.Growth Estimates Quarters
The company's growth estimates for the present quarter and the next is a negative 9.5% and a negative 14.9%, respectively.Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Seattle Genetics's stock is considered to be overbought (>=80).
Yearly Top and Bottom Value
Seattle Genetics's stock is valued at $199.74 at 10:18 EST, above its 52-week high of $183.00.
Revenue Growth
Year-on-year quarterly revenue growth grew by 20.3%, now sitting on 1.86B for the twelve trailing months.
More news about Seattle Genetics (SGEN).